HomeCompareYS vs ORCC

YS vs ORCC: Dividend Comparison 2026

YS yields 196.08% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YS wins by $106.47M in total portfolio value
10 years
YS
YS
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$106.49M
Annual income
$53,157,200.41
Full YS calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — YS vs ORCC

📍 YS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYSORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YS + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YS pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YS
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$45,183,620.35/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, YS beats the other by $45,183,619.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YS + ORCC for your $10,000?

YS: 50%ORCC: 50%
100% ORCC50/50100% YS
Portfolio after 10yr
$53.25M
Annual income
$26,578,600.73/yr
Blended yield
49.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

YS
No analyst data
Altman Z
-2.0
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YS buys
0
ORCC buys
0
No recent congressional trades found for YS or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYSORCC
Forward yield196.08%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$106.49M$21.4K
Annual income after 10y$53,157,200.41$1.04
Total dividends collected$100.24M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: YS vs ORCC ($10,000, DRIP)

YearYS PortfolioYS Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$30,308$19,607.84$11,190$489.61+$19.1KYS
2$87,969$55,539.39$12,229$256.01+$75.7KYS
3$244,784$150,657.53$13,216$130.74+$231.6KYS
4$653,717$391,797.56$14,207$66.02+$639.5KYS
5$1,677,354$977,876.94$15,234$33.17+$1.66MYS
6$4,139,729$2,344,960.75$16,317$16.62+$4.12MYS
7$9,838,287$5,408,777.15$17,468$8.32+$9.82MYS
8$22,540,283$12,013,315.53$18,695$4.16+$22.52MYS
9$49,840,946$25,722,843.02$20,006$2.08+$49.82MYS
10$106,487,012$53,157,200.41$21,407$1.04+$106.47MYS

YS vs ORCC: Complete Analysis 2026

YSStock

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Full YS Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this YS vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YS vs SCHDYS vs JEPIYS vs OYS vs KOYS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.